LTRN Q2 2022 Earnings — Lantern Pharma Inc. Revenue & Financial Results | Market Cap Arena

LTRNLantern Pharma Inc.

$30M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$4M

Net Income

-$4M

EPS (Diluted)

$-0.42

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$289,533

Balance Sheet

Total Assets

$66M

Total Liabilities

$5M

Stockholders' Equity

$61M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$4M	-$2M	-77.3%
Net Income	-$4M	-$2M	-93.9%